Literature DB >> 22093537

The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies.

H Chang-Quan1, W Hui, W Chao-Min, W Zheng-Rong, G Jun-Wen, L Yong-Hong, L Yan-You, L Qing-Xiu.   

Abstract

The association of antihypertensive medication use with cognitive decline (including mild cognitive impairment) or dementia (including Alzheimer's disease (AD), vascular dementia (VD) and any dementia) has still been an area of controversy. This study examined the association of antihypertensive medication use with cognitive decline or dementia using a quantitative meta-analysis of longitudinal studies. EMBASE and MEDLINE were searched for articles published up to Feb 2011. All studies that examined the relationship between antihypertensive medication use and the incidence of dementia or cognitive decline were included. Pooled relative risk (RR) was calculated using fixed and random-effects models. Fourteen studies met our inclusion criteria for this meta-analysis. All subjects were without dementia or cognitive impairment at baseline. There were subjects with (32,658) and without (36,905) antihypertensive medication use. The quantitative meta-analysis showed that there was no significant difference in incidence of AD (RR: 0.90, 95% confidence interval (CI): 0.79-1.03), cognitive decline (RR: 0.97; 95% CI: 0.92-1.03) and cognitive impairment (RR: 0.97; 95% CI: 0.92-1.03). The quantitative meta-analysis showed that the subjects with antihypertensive medication use were lower incidence of VD (RR: 0.67, 95% CI: 0.52-0.87) and any dementia (RR: 0.87; 95% CI: 0.77-0.96) than those without. The quantitative meta-analysis showed that antihypertensive medication use could decrease risk of the development of VD and any dementia, but could not decrease that of AD, cognitive decline and cognitive impairment.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22093537     DOI: 10.1111/j.1742-1241.2011.02810.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  22 in total

1.  Independent and interactive impacts of hypertension and diabetes mellitus on verbal memory: A coordinated analysis of longitudinal data from England, Sweden, and the United States.

Authors:  Amanda Kelly; Matthew Calamia; Andrey Koval; Graciela Muniz Terrera; Andrea M Piccinin; Sean Clouston; Linda B Hassing; David A Bennett; Boo Johansson; Scott M Hofer
Journal:  Psychol Aging       Date:  2016-02-25

Review 2.  Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.

Authors:  Romain Barus; Johana Béné; Julie Deguil; Sophie Gautier; Régis Bordet
Journal:  Br J Pharmacol       Date:  2019-03-31       Impact factor: 8.739

Review 3.  Strategies for dementia prevention: latest evidence and implications.

Authors:  Gopalkumar Rakesh; Steven T Szabo; George S Alexopoulos; Anthony S Zannas
Journal:  Ther Adv Chronic Dis       Date:  2017-06-27       Impact factor: 5.091

Review 4.  Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms.

Authors:  Laure Rouch; Philippe Cestac; Olivier Hanon; Charlène Cool; Catherine Helmer; Béatrice Bouhanick; Bernard Chamontin; Jean-Franҫois Dartigues; Bruno Vellas; Sandrine Andrieu
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

5.  Charlson Comorbidity Index, inappropriate medication use and cognitive impairment : Bermuda Triangle.

Authors:  Kamile Silay; Ahmet Yalcin; Sema Akinci; Fatma Gul Gursoy; Didem Sener Dede
Journal:  Wien Klin Wochenschr       Date:  2017-09-01       Impact factor: 1.704

6.  Bridging the Translation Gap: From Dementia Risk Assessment to Advice on Risk Reduction.

Authors:  Kaarin J Anstey; Ranmalee Eramudugolla; Diane E Hosking; Nicola T Lautenschlager; Roger A Dixon
Journal:  J Prev Alzheimers Dis       Date:  2015

7.  Genotype patterns at CLU, CR1, PICALM and APOE, cognition and Mediterranean diet: the PREDIMED-NAVARRA trial.

Authors:  Elena H Martínez-Lapiscina; Cecilia Galbete; Dolores Corella; Estefania Toledo; Pilar Buil-Cosiales; Jordi Salas-Salvado; Emilio Ros; Miguel A Martinez-Gonzalez
Journal:  Genes Nutr       Date:  2014-03-19       Impact factor: 5.523

8.  Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review.

Authors:  Jean Peters; Andrew Booth; Ruth Peters
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

Review 9.  Prevalence of mild cognitive impairment in patients with hypertension: a systematic review and meta-analysis.

Authors:  Jiawei Qin; Zexiang He; Lijian Wu; Wanting Wang; Qiuxiang Lin; Yiheng Lin; Liling Zheng
Journal:  Hypertens Res       Date:  2021-07-20       Impact factor: 3.872

10.  Cerebrolysin for vascular dementia.

Authors:  Shuhui Cui; Ning Chen; Mi Yang; Jian Guo; Muke Zhou; Cairong Zhu; Li He
Journal:  Cochrane Database Syst Rev       Date:  2019-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.